AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
chloral hydrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 586 | 302-17-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A hypnotic and sedative used in the treatment of INSOMNIA.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | g | O |
| 1 | g | R |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 8300 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 86.37 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 51 | |||
| kinase-selectivity-class | AXL,BRAF,GRK2,MAP2K6,PDK1,PDK2,PIK3CD,PIK3CG | 8 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1840 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Schizophrenia | 875.92 | 179.11 | 184 | 3441 | 14730 | 90610092 |
| Hypomania | 796.70 | 179.11 | 156 | 3469 | 8741 | 90616081 |
| Jaundice cholestatic | 747.90 | 179.11 | 151 | 3474 | 9892 | 90614930 |
| Cholelithiasis | 645.76 | 179.11 | 184 | 3441 | 52322 | 90572500 |
| Psychotic disorder | 572.57 | 179.11 | 150 | 3475 | 31080 | 90593742 |
| Blood bilirubin increased | 532.45 | 179.11 | 152 | 3473 | 43318 | 90581504 |
| Hepatotoxicity | 524.46 | 179.11 | 152 | 3473 | 45690 | 90579132 |
| Asthma-chronic obstructive pulmonary disease overlap syndrome | 432.36 | 179.11 | 85 | 3540 | 4814 | 90620008 |
| Total lung capacity increased | 430.28 | 179.11 | 85 | 3540 | 4936 | 90619886 |
| Sarcoidosis | 366.40 | 179.11 | 85 | 3540 | 10588 | 90614234 |
| Nasal polyps | 364.77 | 179.11 | 85 | 3540 | 10795 | 90614027 |
| Rhinitis allergic | 328.15 | 179.11 | 85 | 3540 | 16700 | 90608122 |
| Cardiac murmur | 326.15 | 179.11 | 86 | 3539 | 18108 | 90606714 |
| Bronchiectasis | 304.11 | 179.11 | 85 | 3540 | 22245 | 90602577 |
| Lung neoplasm malignant | 244.05 | 179.11 | 73 | 3552 | 24200 | 90600622 |
| Hepatic enzyme increased | 225.39 | 179.11 | 153 | 3472 | 360583 | 90264239 |
| Pneumonia | 208.54 | 179.11 | 184 | 3441 | 637875 | 89986947 |
| Chronic obstructive pulmonary disease | 204.47 | 179.11 | 85 | 3540 | 73744 | 90551078 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Respiratory failure | 82.41 | 50.04 | 39 | 584 | 128093 | 42492619 |
| Sedation complication | 73.16 | 50.04 | 15 | 608 | 2904 | 42617808 |
| Hypoventilation | 63.62 | 50.04 | 14 | 609 | 3788 | 42616924 |
| Necrotising enterocolitis neonatal | 51.34 | 50.04 | 8 | 615 | 323 | 42620389 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Schizophrenia | 831.53 | 86.13 | 188 | 4129 | 21638 | 110563344 |
| Hypomania | 784.53 | 86.13 | 157 | 4160 | 10053 | 110574929 |
| Jaundice cholestatic | 705.89 | 86.13 | 153 | 4164 | 14455 | 110570527 |
| Cholelithiasis | 632.54 | 86.13 | 188 | 4129 | 63234 | 110521748 |
| Psychotic disorder | 520.54 | 86.13 | 154 | 4163 | 50783 | 110534199 |
| Hepatotoxicity | 487.30 | 86.13 | 154 | 4163 | 63246 | 110521736 |
| Blood bilirubin increased | 455.94 | 86.13 | 153 | 4164 | 75819 | 110509163 |
| Total lung capacity increased | 442.83 | 86.13 | 87 | 4230 | 5025 | 110579957 |
| Asthma-chronic obstructive pulmonary disease overlap syndrome | 424.09 | 86.13 | 87 | 4230 | 6257 | 110578725 |
| Sarcoidosis | 364.78 | 86.13 | 87 | 4230 | 12492 | 110572490 |
| Nasal polyps | 360.61 | 86.13 | 87 | 4230 | 13113 | 110571869 |
| Rhinitis allergic | 339.03 | 86.13 | 88 | 4229 | 17834 | 110567148 |
| Cardiac murmur | 306.79 | 86.13 | 87 | 4230 | 24541 | 110560441 |
| Bronchiectasis | 273.03 | 86.13 | 87 | 4230 | 36406 | 110548576 |
| Hepatic enzyme increased | 252.38 | 86.13 | 156 | 4161 | 320736 | 110264246 |
| Lung neoplasm malignant | 225.83 | 86.13 | 74 | 4243 | 33768 | 110551214 |
| Chronic obstructive pulmonary disease | 180.48 | 86.13 | 87 | 4230 | 109071 | 110475911 |
| Vomiting | 178.95 | 86.13 | 197 | 4120 | 910478 | 109674504 |
| Pneumonia | 178.05 | 86.13 | 193 | 4124 | 876521 | 109708461 |
| Gastrooesophageal reflux disease | 147.35 | 86.13 | 90 | 4227 | 179886 | 110405096 |
| Condition aggravated | 145.72 | 86.13 | 160 | 4157 | 734676 | 109850306 |
| Nausea | 122.50 | 86.13 | 191 | 4126 | 1235499 | 109349483 |
| Wheezing | 116.58 | 86.13 | 89 | 4228 | 255141 | 110329841 |
| Oedema peripheral | 108.82 | 86.13 | 95 | 4222 | 328565 | 110256417 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05CC01 | NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Aldehydes and derivatives |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D006993 | Hypnotics and Sedatives |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35474 | anxiolytic drug |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35703 | xenobiotic |
| CHEBI has role | CHEBI:35717 | sedative |
| CHEBI has role | CHEBI:38869 | general anaesthetic |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
Related Drugs by ATC class:
N05CC Aldehydes and derivatives 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| General anesthesia | indication | 50697003 | |
| Insomnia | indication | 193462001 | |
| Sedation | off-label use | 72641008 | |
| Proctitis | contraindication | 3951002 | DOID:3127 |
| Gastritis | contraindication | 4556007 | DOID:4029 |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Esophagitis | contraindication | 16761005 | DOID:11963 |
| Inflammatory bowel disease | contraindication | 24526004 | DOID:0050589 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Substance abuse | contraindication | 66214007 | |
| Acute disease of cardiovascular system | contraindication | 128487001 | |
| Acute intermittent porphyria | contraindication | 234422006 | DOID:3890 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | General anesthesia | Indication |
| Cattle | Sedation | Indication |
| Horses | General anesthesia | Indication |
| Horses | Sedation | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Chloropent | Zoetis Inc. | 3 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.9 | acidic |
| pKa2 | 13.19 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4017726 | VUID |
| N0000146094 | NUI |
| D00265 | KEGG_DRUG |
| 2344 | RXNORM |
| C0008161 | UMLSCUI |
| CHEBI:28142 | CHEBI |
| CHEMBL455917 | ChEMBL_ID |
| DB01563 | DRUGBANK_ID |
| D002697 | MESH_DESCRIPTOR_UI |
| 2707 | PUBCHEM_CID |
| 418M5916WG | UNII |
| 3870 | MMSL |
| 4404 | MMSL |
| d00147 | MMSL |
| 001427 | NDDF |
| 273948005 | SNOMEDCT_US |
| 28748001 | SNOMEDCT_US |
| 4017726 | VANDF |
Pharmaceutical products:
None